The following is a summary of “Factors associated with the detection of atrial fibrillation in patients with embolic stroke ...
Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...
These documents have become too technical, too inconsistent, and rely too much on expert opinion, Marco Valgimigli argues.
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...
Tempus AI’s olivia app allows patients to consolidate healthcare data onto a single platform and gain insights using AI.
Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...
Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...
Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...
For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...